香港股市 將收市,收市時間:38 分鐘

Chugai Pharmaceutical Co., Ltd. (CHGCF)

Other OTC - Other OTC 延遲價格。貨幣為 USD。
加入追蹤清單
29.75-2.68 (-8.26%)
收市:11:06AM EDT

Chugai Pharmaceutical Co., Ltd.

2-1-1 Nihonbashi-Muromachi
Chuo 103-8324
Japan
81 3 3281 6611
https://www.chugai-pharm.co.jp

版塊Healthcare
行業Drug Manufacturers - General
全職員工7,604

高階主管

名稱頭銜支付行使價出生年份
Dr. Osamu OkudaPresident, CEO & Representative Director1.39M1963
Mr. Iwaaki TaniguchiExecutive VP, Head of Finance Supervisory Division, CFO & Director1967
Toshiya SasaiExecutive of Investor Relations Group & Corporate Communications Department
Mr. Masayoshi HiguchiVP and Head of Quality, Regulatory Compliance Unit, Business Strategy & Compliance Dept.
Junichi TakanoHead of Marketing & Sales Division
Mr. Shinji HidakaExecutive Vice President
Mr. Junichi EbiharaExecutive Vice President
Dr. Yoshiaki OhashiSVP & Full-time Audit Supervisory Board Member1960
Mr. Tetsuya YamaguchiExecutive VP & Head of PHC Solution Unit
Mr. Yoshiyuki YanoExecutive Vice President
截止 2022年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

公司管治

截至 2024年5月1日 止,Chugai Pharmaceutical Co., Ltd. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中:1;董事會:7;股東權利:2;現金賠償:1。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。